Japan· JP-4291470A1020
エルラナタマブ（遺伝子組換え）
A elranatamab product containing エルラナタマブ（遺伝子組換え）, registered in Japan by ファイザー, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Elranatamab is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FX32 (elranatamab), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 8 of them publish a price we can compare per daily dose
Elranatamab · ATC L01FX32
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- エルラナタマブ（遺伝子組換え）
- Manufacturer
- ファイザー
- Country
- Japan (JP)
- ATC code
- L01FX32
- ATC class
- Elranatamab
- Defined daily dose
- 5.43 mg, P
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Elranatamab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesElrexfioPfizer Laboratories Div Pfizer Inc
- CanadaELREXFIOPFIZER CANADA ULC
- SwitzerlandElrexfio
- CzechiaELREXFIOPfizer Europe MA EEIG, Bruxelles
- BelgiumElrexfio 40 mg/mlPfizer Europe MA
- United KingdomElrexfio 44mg/1.1ml solution for injection vialsPfizer Ltd
- FranceELREXFIO 40 mg/mL, solution injectablePFIZER EUROPE MA EEIG (BELGIQUE)
- SpainELREXFIO 40 MG/ML SOLUCION INYECTABLEPfizer Europe Ma Eeig
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Elrexfio
- Liechtenstein · Elrexfio
- Norway · Elrexfio
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/93eee38b-50f4-4530-a467-0aef304ea2ae GET /v1/drugs/93eee38b-50f4-4530-a467-0aef304ea2ae?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "４４ｍｇ１．１ｍＬ１瓶",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "4291470A1020",
"category": "注射薬",
"price_yen": 558501,
"generic_name": "エルラナタマブ（遺伝子組換え）",
"product_name_jp": null,
"therapeutic_class": "4291",
"transitional_expiry": null
}See everything about elranatamab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.